NASDAQ:ALKS Alkermes (ALKS) Stock Price, News & Analysis $27.88 -0.16 (-0.57%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$27.66▼$28.9550-Day Range$23.01▼$28.0452-Week Range$22.01▼$32.88Volume2.10 million shsAverage Volume1.91 million shsMarket Capitalization$4.72 billionP/E Ratio11.02Dividend YieldN/APrice Target$36.70 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Alkermes alerts: Email Address Alkermes MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.55 Rating ScoreUpside/Downside31.6% Upside$36.70 Price TargetShort InterestBearish9.53% of Shares Sold ShortDividend StrengthN/ASustainability-1.17Upright™ Environmental ScoreNews Sentiment0.42Based on 28 Articles This WeekInsider TradingN/AProj. Earnings Growth-7.56%From $2.25 to $2.08 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.66 out of 5 starsMedical Sector74th out of 936 stocksPharmaceutical Preparations Industry25th out of 436 stocks 4.3 Analyst's Opinion Consensus RatingAlkermes has received a consensus rating of Moderate Buy. The company's average rating score is 2.55, and is based on 7 buy ratings, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageAlkermes has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Alkermes' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.53% of the outstanding shares of Alkermes have been sold short.Short Interest Ratio / Days to CoverAlkermes has a short interest ratio ("days to cover") of 8.9.Change versus previous monthShort interest in Alkermes has recently increased by 17.91%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAlkermes does not currently pay a dividend.Dividend GrowthAlkermes does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAlkermes has received a 60.90% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for physical health", "Antipsychotics", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Alkermes is -1.17. Previous Next 1.9 News and Social Media Coverage News SentimentAlkermes has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 28 news articles for Alkermes this week, compared to 6 articles on an average week.Search InterestOnly 1 people have searched for ALKS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Alkermes to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alkermes insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.89% of the stock of Alkermes is held by insiders.Percentage Held by Institutions95.21% of the stock of Alkermes is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Alkermes' insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Alkermes are expected to decrease by -7.56% in the coming year, from $2.25 to $2.08 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alkermes is 11.02, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.27.Price to Earnings Ratio vs. SectorThe P/E ratio of Alkermes is 11.02, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 112.08.Price to Earnings Growth RatioAlkermes has a PEG Ratio of 0.54. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioAlkermes has a P/B Ratio of 3.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Alkermes' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has led to a massive bull run in the year after it happens. That means we're in the "golden window" right now…Check out the new "Crypto Bull Run Millionaire Blueprint" now! About Alkermes Stock (NASDAQ:ALKS)Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.Read More ALKS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALKS Stock News HeadlinesJuly 27 at 5:58 AM | americanbankingnews.comAlkermes (NASDAQ:ALKS) PT Raised to $32.00 at JPMorgan Chase & Co.July 27 at 12:30 AM | markets.businessinsider.comStrong Buy on Alkermes: Solid Q2 Earnings and Promising Drug Pipeline Drive Positive OutlookJuly 27, 2024 | Crypto 101 Media (Ad)Next opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has led to a massive bull run in the year after it happens. That means we're in the "golden window" right now…July 26 at 7:29 PM | markets.businessinsider.comMaintaining Hold on Alkermes: Weighing Solid Performance Against Seasonal Slowdown and Pipeline UncertaintiesJuly 26 at 8:10 AM | americanbankingnews.comAlkermes (NASDAQ:ALKS) Given New $38.00 Price Target at Robert W. BairdJuly 26 at 7:06 AM | americanbankingnews.comAlkermes (NASDAQ:ALKS) Shares Gap Up to $25.00July 25 at 2:07 PM | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Alkermes (ALKS) and Viking Therapeutics (VKTX)July 25 at 9:04 AM | markets.businessinsider.comStrong Performance and Clinical Promise Uphold Buy Rating for Alkermes with $32 Target PriceJuly 27, 2024 | Crypto 101 Media (Ad)Next opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has led to a massive bull run in the year after it happens. That means we're in the "golden window" right now…July 25 at 9:04 AM | msn.comAlkermes plc (NASDAQ:ALKS) Q2 2024 Earnings Call TranscriptJuly 25 at 9:00 AM | americanbankingnews.comAlkermes (NASDAQ:ALKS) Price Target Raised to $37.00July 24 at 6:51 PM | finance.yahoo.comIs Alkermes plc's (NASDAQ:ALKS) Latest Stock Performance Being Led By Its Strong Fundamentals?July 24 at 6:51 PM | markets.businessinsider.comAlkermes Lags Q2 Earnings EstimatesJuly 24 at 7:59 AM | seekingalpha.comAlkermes plc 2024 Q2 - Results - Earnings Call PresentationJuly 24 at 7:00 AM | prnewswire.comAlkermes plc Reports Second Quarter 2024 Financial ResultsJuly 23, 2024 | markets.businessinsider.comAlkermes earnings: here's what Wall Street expectsJuly 23, 2024 | americanbankingnews.comAlkermes (ALKS) to Release Quarterly Earnings on WednesdayJuly 20, 2024 | americanbankingnews.comAlkermes (NASDAQ:ALKS) Downgraded to Hold at StockNews.comSee More Headlines Receive ALKS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/24/2024Today7/27/2024Next Earnings (Estimated)10/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:ALKS CUSIPG0176710 CIK1520262 Webwww.alkermes.com Phone(531) 772-8000Fax781-890-0524Employees2,100Year Founded1987Price Target and Rating Average Stock Price Target$36.70 High Stock Price Target$50.00 Low Stock Price Target$25.00 Potential Upside/Downside+31.6%Consensus RatingModerate Buy Rating Score (0-4)2.55 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)$2.53 Trailing P/E Ratio11.02 Forward P/E Ratio12.39 P/E Growth0.54Net Income$355.76 million Net Margins19.15% Pretax Margin23.66% Return on Equity23.20% Return on Assets13.52% Debt Debt-to-Equity Ratio0.22 Current Ratio3.16 Quick Ratio2.77 Sales & Book Value Annual Sales$1.66 billion Price / Sales2.84 Cash Flow$2.39 per share Price / Cash Flow11.68 Book Value$7.59 per share Price / Book3.67Miscellaneous Outstanding Shares169,220,000Free Float160,946,000Market Cap$4.72 billion OptionableOptionable Beta0.47 Social Links 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Richard F. Pops (Age 62)Chairman & CEO Comp: $2.61MMr. Blair C. Jackson (Age 51)Interim Principal Financial Officer, Executive VP, Chief Risk Officer & COO Comp: $1.17MMr. David Joseph Gaffin (Age 52)Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary Comp: $1.15MMr. Iain Michael Brown (Age 55)Senior VP & CFO (Leave of Absence) Comp: $950.88kDr. Craig C. Hopkinson M.D. (Age 56)Executive VP of Research & Development and Chief Medical Officer Comp: $1.24MDr. Floyd E. Bloom M.D. (Age 87)Founder Comp: $57.73kMr. Samuel J. Parisi (Age 49)Interim Principal Accounting Officer & VP of Finance Mr. Thomas HarveyChief Information Officer & Senior VP of ITMs. Sandra CoombsSenior Vice President of Corporate Affairs & Investor RelationsMr. Stephen SchiavoSenior Vice President of Human ResourcesMore ExecutivesKey CompetitorsEidos TherapeuticsNASDAQ:EIDXAgios PharmaceuticalsNASDAQ:AGIOPacira BioSciencesNASDAQ:PCRXAtea PharmaceuticalsNASDAQ:AVIRADC TherapeuticsNYSE:ADCTView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpSold 460,277 shares on 7/26/2024Ownership: 1.431%Allspring Global Investments Holdings LLCBought 88,834 shares on 7/26/2024Ownership: 0.124%EFG Asset Management North America Corp.Bought 359 shares on 7/26/2024Ownership: 0.045%AMG National Trust BankBought 35,445 shares on 7/25/2024Ownership: 0.021%Louisiana State Employees Retirement SystemBought 2,500 shares on 7/24/2024Ownership: 0.050%View All Insider TransactionsView All Institutional Transactions ALKS Stock Analysis - Frequently Asked Questions How have ALKS shares performed this year? Alkermes' stock was trading at $27.74 at the beginning of the year. Since then, ALKS shares have increased by 0.5% and is now trading at $27.88. View the best growth stocks for 2024 here. How were Alkermes' earnings last quarter? Alkermes plc (NASDAQ:ALKS) released its quarterly earnings results on Wednesday, July, 24th. The company reported $0.70 EPS for the quarter, meeting the consensus estimate of $0.70. The company's revenue was down 35.4% compared to the same quarter last year. Is Alkermes doing a stock buyback? Alkermes' Board of Directors initiated a share buyback program on Thursday, February 15th 2024, which permits the company to buy back $400,000,000 in outstanding shares, according to EventVestor. This means that the company could reacquire up to 8.2% of its stock through open market purchases. Stock buyback programs are usually an indication that the company's leadership believes its shares are undervalued. What is Richard F. Pops' approval rating as Alkermes' CEO? 119 employees have rated Alkermes Chief Executive Officer Richard F. Pops on Glassdoor.com. Richard F. Pops has an approval rating of 84% among the company's employees. Does Alkermes have any subsidiaries? The following companies are subsidiaries of Alkermes: Rodin Therapeutics. Who are Alkermes' major shareholders? Top institutional shareholders of Alkermes include Bank of New York Mellon Corp (1.43%), Allspring Global Investments Holdings LLC (0.12%), Wedge Capital Management L L P NC (0.07%) and Assenagon Asset Management S.A. (0.05%). Insiders that own company stock include Richard F Pops, Michael J Landine, Shane Cooke, David Joseph Gaffin, Blair Curtis Jackson, Christian Todd Nichols, Nancy Wysenski, Cato T Laurencin, Emily Peterson Alva and Craig C Hopkinson. View institutional ownership trends. How do I buy shares of Alkermes? Shares of ALKS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Alkermes own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alkermes investors own include Gilead Sciences (GILD), Netflix (NFLX), Pfizer (PFE), NVIDIA (NVDA), AbbVie (ABBV), Starbucks (SBUX) and This page (NASDAQ:ALKS) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alkermes plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Alkermes With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
